



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

4 September 2020
EMADOC-628903358-2480

Public summary of opinion on orphan designation

Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-(((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide for the treatment of blastic plasmacytoid dendritic cell neoplasm

On 26 June 2020, orphan designation EU/3/20/2292 was granted by the European Commission to ImmunoGen BioPharma (Ireland) Limited, Ireland, for anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-(((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide (also known as IMG632) for the treatment of blastic plasmacytoid dendritic cell neoplasm.

What is blastic plasmacytoid dendritic cell neoplasm?

Blastic plasmacytoid dendritic cell neoplasm is an aggressive type of blood cancer in which the bone marrow (the spongy tissue inside the large bones, where blood cells are produced) produces large numbers of immature white blood cells called 'plasmacytoid dendritic cells'. These may build up in the bone marrow and take the place of normal blood cells. Most patients develop non-itchy damaged areas in the skin, which often look like bruises or nodules. The disease may also cause enlargement of the spleen or liver and a reduction of the number of circulating blood cells.

Blastic plasmacytoid dendritic cell neoplasm is a life-threatening disease that is associated with poor overall survival.



What is the estimated number of patients affected by the condition?

At the time of designation, blastic plasmacytoid dendritic cell neoplasm affected approximately 0.01 in 10,000 people in the European Union (EU). This was equivalent to a total of around 500 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of blastic plasmacytoid dendritic cell neoplasm. Patients often received radiotherapy (treatment with radiation) and medicines authorised for other types of blood cancers. Some patients were also given stem cell transplantation, a complex procedure where the patient receives stem cells from a matched donor to help restore the bone marrow.

How is this medicine expected to work?

This medicine is made of an antibody (a type of protein) linked to a substance that kills cancer cells. The antibody portion of the medicine attaches to a receptor (target) called CD123, which is found at high levels on the surface of cancerous plasmacytoid dendritic cells. Once attached to the receptor, the medicine is taken up inside the cell where the toxic portion interferes with the production of the cell's DNA (genetic material), causing the death of the cell. This is expected to slow down the progression of the disease.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with blastic plasmacytoid dendritic cell neoplasm were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for the treatment of blastic plasmacytoid dendritic cell neoplasm or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000, the COMP adopted a positive opinion on 20 May 2020, recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

*For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union, Iceland, Liechtenstein, Norway and the United Kingdom. This represents a population of 519,200,000 (Eurostat 2020).

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information

Contact details of the current sponsor for this orphan designation can be found on [EMA website](#).

For contact details of patients' organisations whose activities are targeted at rare diseases see:

- [Orphanet](#), a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;
- [European Organisation for Rare Diseases \(EURORDIS\)](#), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Translations of the active ingredient and indication in all official EU languages¹, Norwegian and Icelandic

Language	Active ingredient	Indication
English	Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide	Treatment of blastic plasmacytoid dendritic cell neoplasm
Bulgarian	Анти-CD123 IgG1 хуманизирано моноклонално антитяло, свързано с N1-(2-(2,5-диоксо-2,5-дихидро-1H-пирол-1-ил)етил)-N6-((S)-1-(((S)-1-((3-(((S)-8-метокси-6-оксо-11,12,12a,13-тетрахидро-6H-бензо[5,6][1,4]дiazепино[1,2-а]индол-9-ил)окси)метил)-5-(((S)-8-метокси-6-оксо-12a,13-дихидро-6Hбензо[5,6][1,4]дiazепино[1,2-а]индол-9-ил)окси)метил)фенил)амино)-1-оксопропан-2-ил)амино)-1-оксопропан-2-ил)адипамид	Лечение на неоплазма с бластни плазмоцитонидни дендритни клетки
Croatian	Anti-CD123 IgG1 humanizirano monoklonsko antitijelo konjugirano na N1-(2-(2,5-diokso-2,5-dihidro-1H-pirol-l-il) etil)-N6-((S)-1-((S)-1-((3-(((S)-8-metoksi-6-okso-11,12,12a,13-tetrahidro-6H-benzo [5,6][1,4] diazepino [1,2-a]indol-9-il) oksi)metil)-5-(((S)-8-metoksi-6-okso-12a,13-dihidro-6Hbenzo[5,6][1,4] diazepino[1,2-a] indol-9-il)oksi) metil)fenil)amino)-1-oksopropan-2-il)amino)-1-oksopropan-2-il)adipamid	Liječenje blastične novotvorine plazmacitodnih dendritičnih stanica
Czech	Anti-CD123 IgG1 humanizovaná monoklonální protilátka konjugovaná s N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)fenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamidem	Léčba nádorů z blastických plasmocytoidních dendritických buněk

¹ At the time of designation

Language	Active ingredient	Indication
Danish	Anti-CD123 IgG1 humaniseret monoklonalt antistof konjureret med N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-(((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamid	Behandling af blastisk plasmacytoid dendritisk celleneoplasi
Dutch	Anti-CD123 IgG1 gehumaniseerd monocloonaal antilichaam geconjugeerd aan N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-(((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide	Behandeling van blastair plasmacytoid dendritische cel neoplasma
Estonian	N1-(2-(2,5-diokso-2,5-dihüdro-1H-pürrool-1-üül)etüül)-N6-(((S)-1-(((S)-1-((3-(((S)-8-metoksü-6-okso-11,12,12a,13-tetrahüdro-6H-benzo[5,6][1,4]diasepiino[1,2-a]indool-9-üül)oksü)metüül)-5-(((S)-8-metoksü-6-okso-12a,13-dihüdro-6Hbenzo[5,6][1,4]diasepiino[1,2-a]indool-9-üül)oksü)metüül)fenüül)amino)-1-oksopropaan-2-üül)amino)-1-oksopropaan-2-üül)adipamiidiga konjugeeritud anti-CD123 IgG1 inimese monoklonaalne antikeha	Blastsete plasmatsütoidsete dendriitrakkudega kasvaja ravi
Finnish	Anti-CD123 IgG1 humanisoitu monoklonaalinen vasta-aine konjugoituna N1-(2-(2,5-diokso-2,5-dihydro-1H-pyrrol-1-yyli)etyyli)-N6-(((S)-1-(((S)-1-((3-(((S)-8-metoksi-6-okso-11,12,12a,13-tetrahydro-6H-bentso[5,6][1,4]diatsepino[1,2-a]indol-9-yyli)oksi)metyyli)-5-(((S)-8-metoksi-6-okso-12a,13-dihydro-6Hbentso[5,6][1,4]diatsepino[1,2-a]indol-9-yyli)oksi)metyyli)fenyyli)amino)-1-oksopropan-2-yyli)amino)-1-oksopropan-2-yyli)adipamidiin	Blastisen plasmasytoidisen dendriittisolukasvaimen hoito

Language	Active ingredient	Indication
French	Anticorps monoclonal humanisé IgG1 anti-CD123 conjugué à N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide	Traitement de la tumeur à cellules dendritiques plasmacytoïdes blastiques
German	Anti-CD123 IgG1 humanisierter monoklonaler Antikörper konjugiert an N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamid	Behandlung von blastischer plasmazytoider dendritischer Zell-Neoplasie
Greek	Αντι-CD123 IgG1 ανθρωποποιημένο μονοκλωνικό αντίσωμα συζευγμένο σε N1-(2-(2,5-διοξο-2,5-διυδρο-1H-πυρολ-1-υλ)αιθυλ)-N6-((S)-1-(((S)-1-((3-(((S)-8-μεθοξυ-6-οξο-11,12,12a,13-τετραϋδρο-6H-βενζο[5,6][1,4]διαζεπινό[1,2-a]ινδολ-9-υλ)οξυ)μεθυλ)-5-(((S)-8-μεθοξυ-6-οξο-12a,13-διυδρο-6Hβενζο[5,6][1,4]διαζεπινό[1,2-a]ινδολ-9-υλ)οξυ)μεθυλ)φαινυλ)αμινο)-1-οξοπροπαν-2-υλ)αμινο)-1-οξοπροπαν-2-υλ)αδιπαμίδη	Θεραπεία νεοπλασματος από βλαστικά πλασματοκυτταροειδή δένδριτικά κύτταρα
Hungarian	N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamid-hoz konjugált CD123 IgG1-elleni humanizált monoklonális antitest	Plazmacitoid dendritikus blastsejtes tumor kezelése
Italian	Anticorpo monoclonale umanizzato IgG1 anti-CD123 coniugato a N1-(2-(2,5-diosso-2,5-diidro-1H-pirrol-1-yl)etil)-N6-((S)-1-(((S)-1-((3-(((S)-8-metossi-6-osso-11,12,12a,13-tetraidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)ossi)metil)-5-(((S)-8-metossi-6-osso-12a,13-diidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)ossi)metil)fenil)amino)-1-ossopropan-2-yl)amino)-1-ossopropan-2-yl)adipamide	Trattamento della neoplasia a cellule dendritiche plasmacitoidi blastiche

Language	Active ingredient	Indication
Latvian	Pret CD123 vērsta IgG1 humanizēta monoklonālā antivielā, kas konjugēta ar N1-(2-(2,5-diokso-2,5-dihidro-1H-pirrol-1-il)etil)-N6-(((S)-1-((3-(((S)-8-metoksi-6-okso-11,12,12a,13-tetrahidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oksi)metil)-5-(((S)-8-metoksi-6-okso-12a,13-dihidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oksi)metil)fenil)amino)-1-oksopropān-2-il)amino)-1-oksopropān-2-il)adipamīdu	Blastisko plazmacitoīdo dendrītu šūnu audzēja ārstēšana
Lithuanian	Humanizuotas anti-CD123 IgG1 monokloninis antikūnas, sujungtas su N1-2-(2,5-diokso-2,5-dihidro-1H-pirol-1-il)etil)-N6-(((S)-1-((3-(((S)-8-metoksi-6-okso-11,12,12a,13-tetrahidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oksi)metil)-5-(((S)-8-metoksi-6-okso-12a,13-dihidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oksi)metil)fenil)amino)-1-oksopropan-2-il)amino)-1-oksopropan-2-il)adipamidas	Blastinių plazmacitoidinių dendritinių ląstelių neoplazmų gydymas
Maltese	Antikorp monoklonali umanizzat IgG1 anti-CD123 konjugat ma' N1-(2-(2,5-diosso-2,5-diidro-1H-pirrol-1-yl)etil)-N6-(((S)-1-((3-(((S)-8-metossi-6-osso-11,12,12a,13-tetraidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)ossi)metil)-5-(((S)-8-metossi-6-osso-12a,13-diidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)ossi)metil)fenil)amino)-1-ossopropan-2-yl)amino)-1-ossopropan-2-yl)adipamid	Kura ta' neoplasma tač-čelloli dendritiçi plasmacitojde blastiçi
Polish	Humanizowane monoklonalne przeciwciało IgG1 nakierowane przeciw CD123, zkonjugowane z N1-(2-(2,5-diokso-2,5-dihydro-1H-pirol-1-yl)etylo)-N6-(((S)-1-((3-(((S)-8-metoksy-6-okso-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indolo-9-yl)oksy)metylo)-5-(((S)-8-metoksy-6-okso-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indolo-9-yl)oksy)metylo)fenilo)amino)-1-oksopropan-2-ylo)amino)-1-oksopropan-2-ylo)adipamidem	Leczenie nowotworu blastycznych plazmacytoidalnych komórek dendrytycznych
Portuguese	Anticorpo monoclonal IgG1 humanizado anti-CD123, conjugado com adipamida de N1-(2-(2,5-dioxo-2,5-di-hidro-1H-pirrol-1-il)etil)-N6-(((S)-1-((3-(((S)-8-metoxi-6-oxo-11,12,12a,13-tetra-hidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oxi)metil)-5-(((S)-8-metoxi-6-oxo-12a,13-di-hidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oxi)metil)fenil)amino)-1-oxopropan-2-il)amino)-1-oxopropan-2-il)	Tratamento da neoplasia blástica de células dendríticas plasmacitoides

Language	Active ingredient	Indication
Romanian	Anticorp monoclonal umanizat IgG1 anti-CD123 conjugat cu N1-(2-(2,5-dioxo-2,5-dihidro-1H-pirol-1-il)etil)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoxi-6-oxo-11,12,12a,13-tetrahidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oxi)metil)-5-(((S)-8-metoxi-6-oxo-12a,13-dihidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oxi)metil)fenil)amino)-1-oxopropan-2-il)amino)-1-oxopropan-2-il)adipamidă	Tratamentul neoplasmului cu celule dendritice plasmacitoide blastice
Slovak	Anti-CD123 IgG1 humanizovaná monoklonálna protilátka konjugovaná na N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)etyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoxi-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)metyl)-5-(((S)-8-metoxi-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)metyl)fenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamid	Liečba neoplázie z blastických plazmocytoidných dendritických buniek
Slovenian	Anti-CD123 IgG1 humanizirano monoklonslo protitelo konjugirano z N1-(2-(2,5-diokso-2,5-dihidro-1H-pirol-1-il)etil)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoksi-6-okso-11,12,12a,13-tetrahidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oksi)metil)-5-(((S)-8-metoks-6-okso-12a,13-dihidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oksi)metil)fenil)amino)-1-oksoopropan-2-il)amino)-1-oksoopropan-2-il)adipamide	Zdravljenje neoplazme blastnih plazmacitoidnih dendritičnih celic
Spanish	Anticuerpo monoclonal IgG1 anti-CD123 conjugado a N1-(2-(2,5-dioxo-2,5- dihidro-1H-pirol-1-il)etil)-N6((S)-1-(((S)-1-((3-(((S)8-metoxi-6-oxo-11,12,12ª,13-tetrahidro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-il)oxi)metal)-5-(((S)-8-metoxi-6-oxo-12a,13-dihidro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-il)amino)-1-oxopropan-2-il)adipamide.	Tratamiento de neoplasia de células blásticas dendríticas plasmocitoides
Swedish	Anti-CD123 IgG1 human monoclonal antikropp konjugerad till N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)etyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoxi-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-(((S)-8-metoxi-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)metyl)fenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamid	Behandling av blastisk plasmacytoid dendritisk cellneoplasi

Language	Active ingredient	Indication
Norwegian	Anti-CD123 IgG humanisert monoklonalt antistoff konjugert til N1-(2-(2,5-diokso-2,5-dihydro-1H-pyrrol-1-yl)etyl)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoksy-6-okso-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oksy)metyl)-5-(((S)-8-metoksy-6-okso-12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oksy)metyl)fenyl)amino)-1-oksopropan-2-yl)amino)-1-oksopropan-2-yl)adipamid	Behandling av blastisk plasmacytoid dendrittisk celle-neoplasi
Icelandic	Mannaðlagað einstofna IgG1 mótefni gegn CD123 tengt N1-(2-(2,5-díoxó-2,5-díhýdró-1H-pýrról-1-yl)etýl)-N6-((S)-1-(((S)-1-((3-(((S)-8-metoxý-6-oxó-11,12,12a,13-tetrahýdró-6H-benzó[5,6][1,4]díazepínól [1,2-a]indól-9-yl)oxý)metýl)-5-(((S)-8-metoxý-6-oxó-12a,13-díhýdró-6Hbenzó[5,6][1,4]díazepínó[1,2-a]indól-9-ýl)oxý)metýl)fenýl)amínó)-1-oxóprópan-2-ýl)amínó)-1-oxóprópan-2-ýl)adípamíð	Meðferð við griplu æxlisvexti í plasmakímfrumum